• IONS

Ionis stock rises following FDA approval of TRYNGOLZA

Ionis Pharmaceuticals gains FDA approval for TRYNGOLZA™, the first treatment for familial chylomicronemia syndrome, aiding patient care and marking a pivotal commercial advancement.